Cargando…

Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain

We report on the ongoing project “A Novel Therapeutic to Ameliorate Chronic Pain and Reduce Opiate Use.” Over 100 million adults in the U.S. suffer from intermittent or constant chronic pain, and chronic pain affects at least 10% of the world’s population. The primary pharmaceuticals for treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabakoff, Boris, Hoffman, Paula L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591148/
https://www.ncbi.nlm.nih.gov/pubmed/33117893
http://dx.doi.org/10.20900/jpbs.20200022
_version_ 1783600934722469888
author Tabakoff, Boris
Hoffman, Paula L.
author_facet Tabakoff, Boris
Hoffman, Paula L.
author_sort Tabakoff, Boris
collection PubMed
description We report on the ongoing project “A Novel Therapeutic to Ameliorate Chronic Pain and Reduce Opiate Use.” Over 100 million adults in the U.S. suffer from intermittent or constant chronic pain, and chronic pain affects at least 10% of the world’s population. The primary pharmaceuticals for treatment of chronic pain have been natural or synthetic opioids and the use of opioids for pain treatment has resulted in what has been called an “epidemic” of opioid abuse, addiction and lethal overdoses. We have, through a process of rational drug design, generated a novel chemical entity (NCE) and have given it the name Kindolor. Kindolor is a non-opiate, non-addicting molecule that was developed specifically to simultaneously control the aberrant activity of three targets on the peripheral sensory system that are integral in the development and propagation of chronic pain. In our initial preclinical studies, we demonstrated the efficacy of Kindolor to reduce or eliminate chronic pain in five animal models. The overall goal of the project is to complete the investigational new drug (IND)-enabling preclinical studies of Kindolor, and once IND approval is gained, we will proceed to the clinical Phase Ia and 1b safety studies and a Phase 2a efficacy study. The work is in its second year, and the present report describes progress toward our overall goal of bringing our compound to a full Phase 2 ready stage.
format Online
Article
Text
id pubmed-7591148
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-75911482020-10-27 Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain Tabakoff, Boris Hoffman, Paula L. J Psychiatr Brain Sci Article We report on the ongoing project “A Novel Therapeutic to Ameliorate Chronic Pain and Reduce Opiate Use.” Over 100 million adults in the U.S. suffer from intermittent or constant chronic pain, and chronic pain affects at least 10% of the world’s population. The primary pharmaceuticals for treatment of chronic pain have been natural or synthetic opioids and the use of opioids for pain treatment has resulted in what has been called an “epidemic” of opioid abuse, addiction and lethal overdoses. We have, through a process of rational drug design, generated a novel chemical entity (NCE) and have given it the name Kindolor. Kindolor is a non-opiate, non-addicting molecule that was developed specifically to simultaneously control the aberrant activity of three targets on the peripheral sensory system that are integral in the development and propagation of chronic pain. In our initial preclinical studies, we demonstrated the efficacy of Kindolor to reduce or eliminate chronic pain in five animal models. The overall goal of the project is to complete the investigational new drug (IND)-enabling preclinical studies of Kindolor, and once IND approval is gained, we will proceed to the clinical Phase Ia and 1b safety studies and a Phase 2a efficacy study. The work is in its second year, and the present report describes progress toward our overall goal of bringing our compound to a full Phase 2 ready stage. 2020-10-05 2020 /pmc/articles/PMC7591148/ /pubmed/33117893 http://dx.doi.org/10.20900/jpbs.20200022 Text en This is an open access article distributed under the terms and conditions of Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Article
Tabakoff, Boris
Hoffman, Paula L.
Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain
title Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain
title_full Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain
title_fullStr Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain
title_full_unstemmed Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain
title_short Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain
title_sort controlling the “opioid epidemic”: a novel chemical entity (nce) to reduce or supplant opiate use for chronic pain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591148/
https://www.ncbi.nlm.nih.gov/pubmed/33117893
http://dx.doi.org/10.20900/jpbs.20200022
work_keys_str_mv AT tabakoffboris controllingtheopioidepidemicanovelchemicalentityncetoreduceorsupplantopiateuseforchronicpain
AT hoffmanpaulal controllingtheopioidepidemicanovelchemicalentityncetoreduceorsupplantopiateuseforchronicpain